2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1Non-small cell lung cancerCell lung cancerRenal cell carcinomaPD-L1Lung cancerDisease progressionCommon treatment-related adverse eventsPD-1/PD-L1 inhibitorsTreatment-related adverse eventsPhase 2 doseSubstantial clinical challengeUnconfirmed partial responseDose-limiting toxicityPD-L1 inhibitorsPhase I trialDose-escalation designPro-inflammatory cytokinesMultiple tumor typesAsymptomatic elevationStable diseaseIntolerable toxicityAdverse eventsMedian durationPartial response
2010
Metachronous Primary Melanoma and Lymphoma
McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. Metachronous Primary Melanoma and Lymphoma. Annals Of Plastic Surgery 2010, 64: 229-232. PMID: 20098111, DOI: 10.1097/sap.0b013e3181a13dbf.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaTumor RegistryYale-New Haven HospitalConnecticut Tumor RegistryEffect of treatmentStudy patientsCutaneous melanomaSurvival differencesPrimary melanomaLymphomaPatientsMelanomaViral inductionDiagnosisGenetic mutationsSurvivalRegistryLonger intervalsMalesGender comparisonsFurther researchImmunosuppressionMalignancyNeoplasmsHospital
1999
Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma
Poo‐Hwu W, Ariyan S, Lamb L, Papac R, Zelterman D, Hu G, Brown J, Fischer D, Bolognia J, Buzaid A. Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma. Cancer 1999, 86: 2252-2258. PMID: 10590365, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2252::aid-cncr12>3.0.co;2-q.Peer-Reviewed Original ResearchConceptsCancer stage IAmerican Joint CommitteePatient education programStage IYale Melanoma UnitSurveillance scheduleSymptomatic recurrenceMelanoma UnitSurveillance examinationsJoint CommitteeOverall survival rateStage of diseaseDetection of recurrenceAsymptomatic recurrenceAsymptomatic patientsDistant recurrenceLocoregional recurrenceHazard ratioDisease recurrenceInitial visitMore recurrencesMost recurrencesLate recurrenceMelanoma patientsRecurrence group